Literature DB >> 26711337

Intratumoral LIGHT Restores Pericyte Contractile Properties and Vessel Integrity.

Anna Johansson-Percival1, Zhi-Jie Li1, Devina D Lakhiani1, Bo He1, Xiao Wang2, Juliana Hamzah2, Ruth Ganss3.   

Abstract

Normalization of the tumor vasculature is an emerging concept shown to improve anti-cancer therapy. However, there are currently no clinical interventions that effect long-lasting normalization. Here, we have developed a strategy for normalization by specific intratumoral delivery of LIGHT/TNFSF14. Importantly, normalization occurs by induced expression of contractile markers in intratumoral pericytes, which in turn re-establishes tight pericyte-vessel alignment. Restoring vessel integrity improves tumor perfusion and acts as adjuvant to chemo- and immunotherapy. Mechanistically, intratumoral LIGHT induces pericyte differentiation and normalization via Rho kinase signaling. Minute amounts of LIGHT act in a paracrine fashion to trigger an amplifying cascade involving transforming growth factor β (TGF-β) from peri-vascular macrophages. That these effects can be reproduced by adoptive transfer of LIGHT-stimulated macrophages alone demonstrates their central role in regulating pericyte differentiation. Our findings highlight a crucial role of pericyte contractile properties in vascular normalization, effected by macrophage signaling, thus providing so far unexplored anti-cancer opportunities.
Copyright © 2015 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26711337     DOI: 10.1016/j.celrep.2015.12.004

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  27 in total

1.  Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation.

Authors:  Elizabeth Allen; Arnaud Jabouille; Lee B Rivera; Inge Lodewijckx; Rindert Missiaen; Veronica Steri; Kevin Feyen; Jaime Tawney; Douglas Hanahan; Iacovos P Michael; Gabriele Bergers
Journal:  Sci Transl Med       Date:  2017-04-12       Impact factor: 17.956

Review 2.  Anti-angiogenic agents - overcoming tumour endothelial cell anergy and improving immunotherapy outcomes.

Authors:  Zowi R Huinen; Elisabeth J M Huijbers; Judy R van Beijnum; Patrycja Nowak-Sliwinska; Arjan W Griffioen
Journal:  Nat Rev Clin Oncol       Date:  2021-04-08       Impact factor: 66.675

3.  Tumour vessel normalization and immune checkpoint blockade: a new synergism.

Authors:  Ruth Ganss
Journal:  Immunol Cell Biol       Date:  2017-05-23       Impact factor: 5.126

Review 4.  Trial watch: Immune checkpoint blockers for cancer therapy.

Authors:  Claire Vanpouille-Box; Claire Lhuillier; Lucillia Bezu; Fernando Aranda; Takahiro Yamazaki; Oliver Kepp; Jitka Fucikova; Radek Spisek; Sandra Demaria; Silvia C Formenti; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2017-08-31       Impact factor: 8.110

5.  TRPC6 regulates phenotypic switching of vascular smooth muscle cells through plasma membrane potential-dependent coupling with PTEN.

Authors:  Takuro Numaga-Tomita; Tsukasa Shimauchi; Sayaka Oda; Tomohiro Tanaka; Kazuhiro Nishiyama; Akiyuki Nishimura; Lutz Birnbaumer; Yasuo Mori; Motohiro Nishida
Journal:  FASEB J       Date:  2019-06-04       Impact factor: 5.191

6.  Transient tissue priming via ROCK inhibition uncouples pancreatic cancer progression, sensitivity to chemotherapy, and metastasis.

Authors:  Claire Vennin; Venessa T Chin; Sean C Warren; Morghan C Lucas; David Herrmann; Astrid Magenau; Pauline Melenec; Stacey N Walters; Gonzalo Del Monte-Nieto; James R W Conway; Max Nobis; Amr H Allam; Rachael A McCloy; Nicola Currey; Mark Pinese; Alice Boulghourjian; Anaiis Zaratzian; Arne A S Adam; Celine Heu; Adnan M Nagrial; Angela Chou; Angela Steinmann; Alison Drury; Danielle Froio; Marc Giry-Laterriere; Nathanial L E Harris; Tri Phan; Rohit Jain; Wolfgang Weninger; Ewan J McGhee; Renee Whan; Amber L Johns; Jaswinder S Samra; Lorraine Chantrill; Anthony J Gill; Maija Kohonen-Corish; Richard P Harvey; Andrew V Biankin; T R Jeffry Evans; Kurt I Anderson; Shane T Grey; Christopher J Ormandy; David Gallego-Ortega; Yingxiao Wang; Michael S Samuel; Owen J Sansom; Andrew Burgess; Thomas R Cox; Jennifer P Morton; Marina Pajic; Paul Timpson
Journal:  Sci Transl Med       Date:  2017-04-05       Impact factor: 17.956

7.  De novo induction of intratumoral lymphoid structures and vessel normalization enhances immunotherapy in resistant tumors.

Authors:  Anna Johansson-Percival; Bo He; Zhi-Jie Li; Alva Kjellén; Karen Russell; Ji Li; Irma Larma; Ruth Ganss
Journal:  Nat Immunol       Date:  2017-09-11       Impact factor: 25.606

8.  Vascular targeting of LIGHT normalizes blood vessels in primary brain cancer and induces intratumoural high endothelial venules.

Authors:  Bo He; Arnaud Jabouille; Veronica Steri; Anna Johansson-Percival; Iacovos P Michael; Venkata Ramana Kotamraju; Reimar Junckerstorff; Anna K Nowak; Juliana Hamzah; Gabriel Lee; Gabriele Bergers; Ruth Ganss
Journal:  J Pathol       Date:  2018-04-20       Impact factor: 7.996

Review 9.  Targeting ROCK activity to disrupt and prime pancreatic cancer for chemotherapy.

Authors:  Claire Vennin; Nicola Rath; Marina Pajic; Michael F Olson; Paul Timpson
Journal:  Small GTPases       Date:  2017-10-03

10.  Stromal cell diversity associated with immune evasion in human triple-negative breast cancer.

Authors:  Sunny Z Wu; Daniel L Roden; Chenfei Wang; Holly Holliday; Kate Harvey; Aurélie S Cazet; Kendelle J Murphy; Brooke Pereira; Ghamdan Al-Eryani; Nenad Bartonicek; Rui Hou; James R Torpy; Simon Junankar; Chia-Ling Chan; Chuan En Lam; Mun N Hui; Laurence Gluch; Jane Beith; Andrew Parker; Elizabeth Robbins; Davendra Segara; Cindy Mak; Caroline Cooper; Sanjay Warrier; Alistair Forrest; Joseph Powell; Sandra O'Toole; Thomas R Cox; Paul Timpson; Elgene Lim; X Shirley Liu; Alexander Swarbrick
Journal:  EMBO J       Date:  2020-08-13       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.